Lorenzo Pellegrini

Lorenzo Pellegrini is the Founder and Chief Operating Officer of Palladio Biosciences. Prior to founding Palladio, Lorenzo was a partner at Care Capital, a leading private equity and venture capital firm investing in drug development companies. During his twelve-year tenure at Care Capital, Lorenzo co-founded and served on the board of several portfolio companies, including Minerva Neurosciences (NASDAQ: NERV), Biocritica, and Sentinella Pharmaceuticals, among others. He also led the firm’s investments in Elevation Pharmaceuticals (acquired by Sunovion), Anacor Pharmaceuticals (acquired by Pfizer) and Agile Therapeutics (NASDAQ: AGRX). Before joining Care Capital, Lorenzo conducted pre- and post-doctoral research in the Department of Cell Biology at Yale University and at the Max-Planck-Institute for Brain Research in Frankfurt am Main. His original research work was published in leading peer-reviewed scientific journals such as Nature, Cell and Neuron.

Lorenzo received a Laurea in Chemistry, summa cum laude, from the University of Padova, Italy; a Ph.D. in Biochemistry from the Max-Planck-Institute for Brain Research in Frankfurt am Main, Germany; and an M.B.A. with honors from The Wharton School of the University of Pennsylvania.